Introduction
Hematopoietic stem cells (HSCs) are important targets for gene therapy of genetic disorders of the blood system since they have the ability to self-renew and are capable of differentiating into all blood lineages. Oncoretroviral vectors have been the classical gene delivery vehicles for hematopoietic cells, including hematopoietic stem cells. High efficiency gene delivery of murine hematopoietic stem cells can be accomplished using oncoretroviral vectors but efficient transduction of hematopoietic stem cells from humans or large outbred animals has been more problematic. [1] [2] [3] [4] The recently published successful gene therapy for severe combined immune deficiency-X1 (SCID) due to ␥ c chain deficiency has been a breakthrough in the gene therapy field and provides proof that this therapeutic modality works in practice. 5 While these advances are encouraging, problems remain. The success with the SCID ␥ c chain deficiency is based on in vivo selection of early lymphoid progenitors following gene transfer of the ␥ c chain gene into autologous CD34
+ bone marrow cells that are subsequently transplanted back to the patient. All T cells and NK cells from the treated patients contained the transgene while only 1% of the myeloid progeny cells contained the vector. This indicates that the gene transfer efficiency into hematopoietic stem cells has been approximately 1% and that the gene modified lymphoid progenitor cells will be selectively grown and differentiated in vivo upon stimulation by IL- 2, IL-7 and IL-15 while the unmodified cells die due to the lack of the cytokine receptors for IL-2, IL-4, IL-7, IL-9, IL-15, of which the ␥ c chain is a part. Since gene replacement of most genetic defects in hematopoietic cells will not lead to in vivo selection, gene transfer efficiencies that are substantially higher than 1% will be needed for treatment of these disorders.
Suboptimal gene transfer efficiency into human hematopoietic stem cells using oncoretroviral vectors is to a large extent due to the quiescent nature of hematopoietic stem cells during steady-state hematopoiesis. At any point in time, most hematopoietic stem cells are in G 0 and to a lesser extent in G 1 , while very few are in active cell cycle (G 2 /S/M). [6] [7] [8] Since active cell cycle is a requirement for transduction by oncoretroviral vectors, 9,10 the hematopoietic cells need to be stimulated by growth factors prior to transduction. Active growth stimulation ex vivo by three or more cytokines for 3-4 days is common practice to allow enough time for active cycling of primitive hematopoietic cells prior to and during oncoretroviral transduction. [11] [12] [13] While it has been well documented that this growth stimulation of early hematopoietic cells improves gene transfer efficiency, it has detrimental effects on engraftment during bone marrow transplantation. Hematopoietic progenitor and stem cells in G 2 /S/M engraft poorly compared to cells in G 0 and G 1 . 7, 8, 14, 15 These difficulties have focused attention on the use of lentiviral vectors for transduction of human hematopoietic stem cells (HSCs) in order to achieve high gene transfer efficiency and efficient engraftment of transduced hematopoietic stem cells.
Although many species-specific lentiviruses exist, most preclinical gene therapy experiments have been performed using vectors based on the human immunodeficiency virus type-1 (HIV-1), and these represent the most advanced lentiviral vectors to date. [16] [17] [18] [19] [20] [21] Because the HIV-1 envelope protein binds specifically to receptors on macrophages and T cells, another envelope protein has to be used to allow the vector to enter HSCs. Therefore, lentiviral vector particles pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G) have been used because they can enter a large variety of target cells due to the ubiquity of the VSV-G phospholipid receptor, and they can easily be concentrated by ultracentrifugation. 16, 22, 23 Figure 1 shows how lentiviral vectors are generated using a transient transfection packaging system where the transfer vector plasmid is transfected into 293-T cells with plasmids encoding the VSV-G gene and the HIV-1 gag, pol and rev genes. This packaging system cannot create wild-type HIV-1 because the genes for the HIV-1 env and the accessory protein genes are lacking. The system described in Figure 1 is the third generation lentiviral vector system 17 where the accessory protein genes (essential for HIV-1 pathogenesis) are lacking and the gag and pol genes on one hand and the rev gene on the other are encoded by separate plasmids. Recently, a third generation packaging cell line for HIV-1 vectors has become available. 24 In this cell line the production of the gag-pol and the
Figure 1
Production of HIV-1-based lentiviral vectors. The figure shows four constructs used to produce third generation lentiviral vectors. There are two packaging constructs, one expressing the gag and pol genes and another expressing the rev gene. A third plasmid expresses the VSV-G envelope protein. The vector plasmid contains a chimeric LTR, consisting mostly of the Rous sarcoma virus (RSV) LTR fused to the U5 region of the HIV LTR. The vector contains the ⌿ packaging signal that is absent in the packaging constructs (to prevent packaging the RNA of the packaging constructs into vector particles), and the rev responsive element, a promoter (P) and the transgene. These four constructs are transiently transfected into 293-T cells and the supernatant is harvested after approximately 48 h. The supernatant can be concentrated 100 to 1000-fold by spinning in an ultracentrifuge. SD indicates splice donor, SA splice acceptor and CMV indicates the promoter/enhancer from cytomegalovirus. Grey boxes in the vector indicate parts of the HIV-1 LTR. The 3′ LTR in the vector is of the self-inactivating (SIN) variety and this LTR becomes the 5′ LTR as well in the provirus, which integrates into the target cells. The figure is modified from Dull et al. 17 VSV-G proteins is controlled by the tet0 promoter, which is regulatable, by doxycyclin. The gag-pol and the VSV-G plasmids are integrated into the genome of the packaging cell in two separate places and their gene products can be induced by doxycyclin treatment. Figure 2 shows a scheme demonstrating the generation of this cell line by Trono and colleagues. The advantages of producing vector particles from a cell line with permanently integrated vector packaging sequences is that reproducible high-quality, high-titer vector supernatants can be made, and there is a lower theoretical Production of a permanent packaging cell for HIV-1-based vectors. In the first step the vector, packaging constructs and the VSV-G envelope construct are transfected into 293 cells as explained in Figure 1 to produce a cell line that can express the rev protein and the envelope and gag-pol proteins upon induction. The packaging cell line that is created in step 1 contains chromosome integrated constructs that express the VSV-G and rev genes by a tetracyclin regulatable promoter and the tTA transactivator and gag-pol genes are expressed by constitutive promoters. The gag-pol construct is shown in Figure 1 . The gag-pol transcripts are quickly degraded in the nucleus without the rev post-transcriptional regulator. Therefore, the gag-pol transcripts are stabilized upon rev induction. The gagpol and VSV-G genes have to be regulatable since their permanent expression would lead to cell death. This cell line is now repeatedly transduced by a vector from transiently transfected 293-T cells in order to get multiple vector integration sites and as a consequence, high-titer producers that can upon induction produce the viral proteins and the vector RNA (steps 2 to 3). In order to suppress expression of the cytotoxic viral proteins the cells are grown in medium containing doxycycline while the cells are maintained. To produce vectors, the viral proteins are induced in the absence of doxycycline. This figure is modified from Klages et al 24 where a description of the generation of the LVG packaging line was made.
risk of the undesirable recombination events that can lead to the generation of replication-competent viral particles.
Lentiviral vectors can transduce quiescent hematopoietic progenitor cells. 25, 26 However, it has also been demonstrated that although human CD34
+ cells in G 0 can be transduced, CD34
+ cells in G 1 or G 2 /S/M are transduced more efficiently. 27 It has been shown that umbilical cord blood CD34 + cells that are mostly in G 0 and G 1 can engraft efficiently in immunocompromised NOD/SCID mice, even after serial transplantation, 14 and that lentiviral vectors can transduce these SCID repopulating cells (SRCs) with 50-60% efficiency. 18, 19, 21 The umbilical cord blood (CB) cells that have been transduced are mostly in G 1 (65-70%) and to a lesser extent in G 0 (20-25%).
14 It remains to be seen whether the high transduction efficiency obtained with lentiviral vectors of these cells can also be obtained when using the more therapeutically relevant 
SPOTLIGHT bone marrow (BM) and peripheral blood (PB) CD34
+ cells, since these latter cell populations have a much higher proportion of G 0 cells than their CB counterparts. 7, 8, 14 We will now review the available data and describe what challenges lie ahead.
Lentiviral transduction of hematopoietic cells
Although lentiviral vectors do transduce non-dividing cells, they unfortunately do not transduce all non-dividing cells. In an experimental setting where human progenitor hematopoietic stem cells (PHSC) were transduced with lentiviral vectors it was shown that: (1) lentiviral transduction is not inhibited by aphidocolin (a cell cycle inhibitor); (2) transduced and untransduced cells contained similar amounts of DNA per cell reflecting that nondividing (N) and dividing (2N) cells were similarly transduced; (3) transduction seemed to be independent of the S phase of the cell cycle, 28 indicating that lentiviral vectors are able to transduce nondividing cells. The same investigators noted, however, that transduction efficiencies were markedly higher if the PHSCs had been cultured in cytokines for 48 h and also that the maximum percentage of cells being transduced rarely exceeded 70%, even at high multiplicities of infection (MOI). In a follow-up study 1 year later, they reported that lentiviral vectors preferentially transduce cells in the G 1 or S/G 2 /M phases of the cell cycle, while cells in G 0 were one-tenth as efficiently transduced. 27 The authors speculated that this depends on lower concentrations of dNTPs in the target cells, which would limit the reverse transcription process. Subsequent studies in our laboratory in the murine setting demonstrate that dNTPs added to the medium only increase transduction efficiency by an extra 10%, suggesting other factors are preventing total transduction of primitive hematopoietic cells. 29 This has implications for a gene therapy setting in the hematopoietic system, firstly because of the sources of stem cells available. Hematopoietic cells can be derived from cord blood (CB), bone marrow (BM) or mobilized peripheral blood (PB). Most of the work with lentiviral transduction of hematopoietic cells has been performed using CB, but autologous BM cells or PB cells are more likely to be used in human gene therapy trials. However, both BM and PB have fewer cells in G 1 and more in G 0 than CB does. It might be necessary to adapt the transduction protocol to these sources by optimizing culture conditions, such as cytokine stimulation or culture time. Second, it will be critical not to stimulate the cells too much, since even stimulation from G 0 to G 1 curtails the engraftability of these stem cells. 7, 8, 15 It may be argued that the main limitation for successful gene therapy of blood disorders lies in the vector's efficiency to transduce hematopoietic stem cells. Lentiviral vectors do offer distinct advantages over oncoretrovirally based vectors, but the full potential of gene therapy will only be met with further modifications to the vectors rendering them truly capable of efficient stem cell transduction.
The key characteristic of the lentiviral vector which distinguishes it from the standard vectors based on oncoretroviruses is that it allows for the infection of primitive nondividing stem cells. The mechanisms behind this central feature, which is to transport the proviral DNA through an intact nuclear membrane, for subsequent integration into the host DNA, remains to be elucidated. During lentiviral infection, both the genome and a number of viral proteins are actively transported into the nucleus via a nuclear pore. It is hypothesized that the proteins and the vector genome form a preintegration complex Leukemia which contains a number of amino acid sequences which localize the complex to nucleus known as the nuclear localization signal (NLS). In 1993 the lentiviral gag matrix protein was implicated in this process. 30 The investigators managed to isolate a sequence of the gag matrix protein that would direct nuclear import when conjugated to a heterologous protein. They also showed that a mutant HIV-1, carrying an amino acid substitution in this NLS, would not replicate in growth-arrested cells. Later, another group showed that the viral protein R (vpr) is also important in the viral nuclear import process. 31 The efficiency of the nuclear localization might be another factor influencing the transduction efficiency seen by lentiviral vectors. The lentiviral vector is in large stripped of its original wt genes, but in an attempt to increase the transduction efficiencies, efforts have been made to identify the NLS in the wt HIV-1 genome and reinsert those to the vector. While the roles of both vpr and the gag matrix protein as NLSs remain controversial, 32,33 a sequence within the pol gene known as the cPPT-CTS fragment or the DNA flap, has been shown to be a cis-determinant of HIV-1 DNA nuclear import. 34 When the DNA flap was inserted into a lentiviral vector, transduction efficiencies with the new vector were significantly higher compared to a vector without the DNA flap. For example, 45% of primary human lymphocytes could be transduced with the DNA flap-containing vector, while the original vector only transduced 15% of the cells. When targeting CD34+ CB cells, the DNA flap-containing vector transduced two-to three-fold more cells than did the control vector.
35,36

Lentiviral vector transgene expression
While optimizations of the lentiviral vector and lentiviral transduction conditions have allowed for improved transduction of SCID repopulating cells, advances were simultaneously being achieved with expression of the transgenes. Lentiviral vectors as they were first developed for gene therapy applications have transgene expression driven from ubiquitously expressing internal promoters such as the cytomegalovirus (CMV) early promoter, or the murine phosphoglycerate kinase (PGK) gene promoter. 18, 19 While these constructs were hailed a success, as they showed persistent expression in serially transplanted NOD/SCID mice, the level of transgene expression was low. In contrast to the HIV-based vectors driving expression from the wt HIV LTR, which have been shown to be capable of high-level transgene expression, 37,38 safety considerations will likely prevent their use in clinical settings. The HIV-1 LTR promoter which requires the expression of the hematologically and neurologically toxic tat protein trans-activator for expression would require the vector to contain the tat gene along with the therapeutic gene. 39, 40 Additionally, the LTR promoter and tat gene contribute a nonessential extra 500 bp of DNA to the vector with sequence homology to the wt HIV and therefore carries an increased risk of homologous recombination with a patient who already has or acquires wt HIV-1 infection. However, in hematological disorders where high-level transgene expression is required in many cell types or in diseases where transgene expression is necessary at an early progenitor cell level, efficient ubiquitously expressing promoters are essential. These ubiquitously expressing promoters must function within the lentiviral vector to produce long-term expression in vivo throughout hematopoietic differentiation into mature hematopoietic lineages. A number of candidate promoters have emerged, for example, the hybrid SPOTLIGHT Leukemia chicken actin promoter containing the CMV enhancer region (CAG) and the human elongation factor-1␣ (EF-1␣) gene promoter. 41 Oncoretroviral LTR promoters from viruses such as the murine stem cell virus (MSCV) or gibon ape leukemia virus (GALV), have also been tested with regards to expression in hematopoietic progenitors. 42 The MND promoter from a modified myeloproliferative sarcoma virus (MPSV) LTR 43 has also been tested within a bovine immunodeficiency lentiviral vector. 44 Testing of these vectors in vitro on human hematopoietic progenitor cells led to the conclusion that high-level transgene expression from a lentiviral vector could be achieved and that most probably the highest expressing vector was that driving expression from the EF-1␣ promoter. 41, 42 Subsequent analyses of expression in vivo in the progeny cells from transduced SRC reveal that the EF-1␣-containing vectors yield high-level expression of the hematopoietic lineages with levels seven-to eight-fold higher than the original PGK lentiviral vector. 45 Studies using murine lin − , c-kit + sca + progenitor cells show long-term high-level expression without loss of expression in all hematopoietic lineages even after serial transplantation. 46 A lentiviral vector which generates extremely high expression levels of the erythroid specific ␤-globin transgene has recently been demonstrated in mice where the level of expression is similar to that found in normal erythroid cells. 20 The vector uses the human ␤-globin promoter and a truncated version of the ␤-globin locus control region to drive expression of the ␤-globin gene, generating high expression levels that are tissue-specific and restricted to the erythroid lineage.
Further modifications to the lentiviral vector were also performed in conjunction with the promoter in order to increase expression levels. Such modifications were the addition of the woodchuck post-transcriptional regulatory element (WPRE), 47 and the removal of the U3 element in the HIV-1 LTR of the vector rendering the vector self-inactivating (SIN vector). 48 The WPRE DNA sequence when placed immediately downstream of the transgene in the vector is thought to increase the stability of the mRNA after transcription. It may also play a role in increasing the efficiency of mRNA processing. Using the WPRE within the lentiviral vector resulted in variable increases in transgene expression in in vitro studies on human hematopoietic cells. 41 The degree of expression seemed dependent on the regulatory elements nearby in the lentiviral vector. For example, expression levels from vectors containing the weaker promoters, PGK and CMV, could be dramatically increased with the WPRE, whereas expression levels were marginally improved or even slightly reduced in vectors containing stronger promoters like CAG and EF-1␣. Other studies using oncoretroviral vectors also show the context dependence of expression using the WPRE. 49 The SIN vectors were originally designed to increase the biosafety of lentiviral vectors by preventing full-length transcription of the proviral vector genome. This reduces the chances of homologous recombination with the wild-type HIV. However, the SIN deletion in which 8 Sp1 transcription factor binding sites are removed may hypothetically influence the level of transgene expression from the vector, particularily in situations where the internal promoter also contains multiple Sp1 sites. 50, 51 Interestingly, the expression levels generated by SIN vectors were also dependent on other regulatory elements present in the vector. For example, in primary human CD34 + cells transduced with the PGK and the PGK SIN vectors, the SIN vector generated only half of the expression level compared with the standard PGK vector. However, in the context of the EF-1␣, the SIN vector increased the expression 1.5-fold. 41 Although thorough analyses of expression from several vectors were performed in vitro, follow-up experiments would be necessary to confirm the ubiquitous expression in vivo throughout hematopoietic differentiation. Experiments in the NOD/SCID mouse demonstrated a high degree of correlation between the in vitro and in vivo expression results where high-level transgene expression could be obtained in all hematopoietic lineages. 45 The comparability of the results also suggests that the rapid screening of new therapeutic vectors driving expression from ubiquitously expressing promoters should be possible in vitro prior to testing in animal models.
One feature of the EF-1␣ promoter is that it contains a 942 bp intron where multiple transcription binding sites are located. Occasionally, during vector production in packaging cell lines, the intron is spliced out of the vector RNA prior to packaging. 42 The spliced vector results in transgene expression being driven from a truncated promoter and studies have shown that the spliced EF-1␣ promoter does not express as well as the non-spliced variant. However, persistent moderate expression can be achieved long term in vivo in the progeny of NODSCID repopulating cells using a truncated (200 bp) EF-1␣ promoter. Therefore, expression from the EF-1␣ promoter may further be optimized by the mutation of the splicing donor and acceptor in the EF-1␣ promoter, thus preventing its truncation during vector production in the packaging cell line.
Biosafety
The third generation lentiviral vector packaging system shown in Figure 1 contains only three of the nine genes in HIV-1, gag, pol and rev. Sixty percent of the viral genome has been removed in the packaging system and this completely excludes the possibility of generating wild-type HIV-1. Since the packaging system shown in Figure 1 has four separate plasmids, the probability of producing a replication-competent recombinant (RCR) is very low. Self-inactivating (SIN) vector systems minimize the likelihood of generating RCRs even further. However, it will be difficult to produce SIN vectors with high titer by transfecting a SIN vector plasmid (intact 5′LTR and 3′ SIN LTR) into the stable packaging cell line as described in Figure 2 , because the plasmid will most likely not integrate into chromosomal sites that are favorable for high-level expression. High titers can only be produced by transducing the packaging cell line using a vector genome with a promoter that can generate the full genomic vector RNA. The lentiviral vector packaging cell line can be used to produce lentiviral vectors that should theoretically be as safe or safer than current oncoretroviral vectors. However, vectors produced in stable producer cell lines generated in the future will have to be tested for the presence of RCR and toxic products before such lines can be used to produce vectors for the clinic. Lentiviral vectors other than those based on HIV-1 have been made although their development is less advanced at present. These are HIV-2 vectors and vectors based on the feline immunodeficiency virus (FIV), bovine immunodeficiency virus, simian immunodeficiency virus (SIV) and the equine infectious anemia virus (EIAV). 44, [52] [53] [54] [55] It has been suggested that these alternative lentiviral vectors may be safer because they are less pathogenic in humans (HIV-2) or are not known to cause human disease. However, it is likely that the greatest risk of using lentiviral vectors in the future is going 567 SPOTLIGHT to be insertional mutagenesis, the same main risk as is likely to ensue with the use of oncoretroviral vectors. Therefore, it is likely that the HIV-1-based vectors will have similar biosafety risks as the other lentiviral vectors mentioned. This discussion presumes that effective testing for microorganisms, toxic products and RCRs can be developed for the lentiviral producer cells as has been possible for the oncoretroviral producers.
Future challenges
While it has been shown that lentiviral gene transfer into HSCs from umbilical cord blood has been demonstrated to be efficient when tested in the NOD/SCID mouse, less is known about the gene transfer efficiency into BM and PB-derived HSCs. While it is likely that efficient gene transfer protocols into these cells can be developed, the transduction conditions must be defined more accurately. Similarly, the transduced HSCs will have to be tested in an autologous transplantation setting in both humans and large outbred animals to test whether long-term reconstituting HSCs can be effectively transduced. So far, the vectors that have been tested in HSCs are mostly single gene vectors. For effective testing of therapeutic vectors it will be important to have lentiviral vectors containing two transcriptional units that can express the therapeutic gene and a selectable marker gene to sufficiently high levels using a safe packaging system. Figure 3 shows a vector that uses an active promoter in the middle of the HIV-1 LTR (the promoter replaces the U3 portion in the LTR) to drive the selectable gene and an internal promoter to drive the therapeutic gene. This vector can be produced in producer cells according to the principles described in Figure 2 . Vectors where promoters are used to replace the U3 region in HIV-1 have been made using the cytomegalovirus and the murine embryonic stem cell virus promoters/enhancers and have been shown to work well in human cells. 24, 42 While the concepts have been developed for the safe production of lentiviral vectors, the new permanent packaging cells will have to be
Figure 3
Examples of vectors (shown as integrated proviruses) expressing two genes, for example, a therapeutic gene and a selectable marker gene. (a) A self-inactivating (SIN) vector where most of the U3 region of the LTR has been deleted. An internal promoter (P) drives the expression of two genes, 1 and 2. The advantage with this design is that the SIN design offers increased safety but the disadvantage is that the expression of gene 2 is going to be reduced since it is placed downstream of an internal ribosomal entry site (IRES) which allows the translation of the second gene from the bicistronic mRNA. The SIN vector cannot be produced in the permanent packaging cell line shown in Figure 2. (b) This vector contains two promoters, one in the LTR (not the HIV-1 promoter for safety reasons) and another promoter (P2) internally. The advantage with this design is that the expression level will be as high as expected from the two individual promoters and here the vector can be produced in the permanent packaging cell line shown in Figure 2 . Since the LTR contains an active promoter there is increased risk from insertional mutagenesis compaired with the construct in (a).
Leukemia tested to assess the quality and safety of the vector preparations that will be generated using these lines. Most importantly, suitable candidate diseases will have to be selected to test the efficiency of lentiviral vector gene therapy. To begin with, it would be wise to select a disease where correction of a fraction of the patients cells would be sufficient to generate a therapeutic effect and where relatively low levels of the transgene product will be sufficient to correct the disease phenotype. Thereafter, more ambitious goals can be pursued where high level expression of the therapeutic gene is required or where a very large fraction of the patient's stem cells need to be corrected, requiring either a very high transduction efficiency or an effective selection of the transduced cells, for example, by a vector gene product that generates a selective advantage in vivo. 56 Recently, several studies have been published which demonstrate stem cell plasticity. Hematopoietic stem cells have been shown to be able to generate heart muscle following myocardial infarction, and liver damage has been repaired in a similar experiment where hematopoietic stem cells were transplanted to mice with liver disease. 57, 58 This stem cell plasticity has implication for the development of cell and gene therapy since it may be possible in the future to generate several separate tissues from one type of adult stem cell which was previously considered to be specialized to the generation of one tissue. An alternate approach would be to deliver genes to more than one type of stem cell to cure a disease, for example, hematopoietic stem cells and mesenchymal stem cells to correct some lysosomal storage disorders where there are defects in hematopoietic cells and connective tissue. In the latter case, lentiviral vectors have an advantage as a gene delivery vehicle to various types of stem cells since some tend to be quiescent and others rapidly dividing. While oncoretroviral vectors can only transduce dividing cells, lentiviral vectors can transduce both dividing and quiescent cells. Therefore, lentiviral vectors are versatile gene delivery vehicles and can be used to transfer genes to many types of stem cells. Rapidly dividing ES cells are efficiently transduced by lentiviral vectors and reduction in lentiviral transgene expression following differentiation of ES cells is considerably less pronounced than the complete silencing or shut-off seen from oncoretroviral transgenes. 59 ES cells may be used in the future to generate specific tissues for cell and gene therapy, and here, lentiviral vectors may be useful for sustained transgene expression.
To conclude, lentiviral vectors are very promising tools for the development of gene therapy using hematopoietic or other types of stem cells as targets. To date, it seems that lentiviral transgenes can be expressed at high levels over time, both when strong general promoters and tissue-specific control elements are used. Therefore, lentiviral vectors will probably be used in many gene therapy approaches in the future within and outside the hematopoietic system.
